KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Finished Goods (2016 - 2025)

Abbott Laboratories' Finished Goods history spans 17 years, with the latest figure at $4.0 billion for Q4 2025.

  • For Q4 2025, Finished Goods rose 7.46% year-over-year to $4.0 billion; the TTM value through Dec 2025 reached $4.0 billion, up 7.46%, while the annual FY2025 figure was $4.0 billion, 7.46% up from the prior year.
  • Finished Goods for Q4 2025 was $4.0 billion at Abbott Laboratories, down from $4.1 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $4.3 billion in Q2 2025 and bottomed at $3.0 billion in Q3 2021.
  • The 5-year median for Finished Goods is $3.9 billion (2023), against an average of $3.7 billion.
  • The largest annual shift saw Finished Goods grew 23.5% in 2022 before it decreased 6.23% in 2024.
  • A 5-year view of Finished Goods shows it stood at $3.1 billion in 2021, then rose by 23.5% to $3.8 billion in 2022, then rose by 3.71% to $3.9 billion in 2023, then dropped by 6.23% to $3.7 billion in 2024, then rose by 7.46% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Finished Goods are $4.0 billion (Q4 2025), $4.1 billion (Q3 2025), and $4.3 billion (Q2 2025).